Jaguar Animal Health (JAGX) AI Stock Analysis

• Market Cap: $4.07M
• Dividend Yield: N/A
• Average Volume (3M): 300.89K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.97
• Revenue Growth: 12.45%
• EPS Growth: -544.23%
• Country: US
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -6.28
• Shares Outstanding: 3,735,837
• 10 Day Avg. Volume: 157,758
• 30 Day Avg. Volume: 300,888
• PEG Ratio: <0.01
• Price to Book (P/B): 0.76
• Price to Sales (P/S): 0.64
• P/FCF Ratio: -0.25
• Enterprise Value/Market Cap: 8.13
• Enterprise Value/Revenue: 2.81
• Enterprise Value/Gross Profit: 3.64
• Enterprise Value/Ebitda: -0.80
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.95 ▼(-25.63% Downside)

The score is held down primarily by weak financial performance (large ongoing losses, high leverage, and significant cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Corporate news is constructive on crofelemer, but potential dilution and the lack of profitability/positive cash flow keep the overall score low.

Positive Factors

Revenue Growth

The consistent revenue growth indicates a strong demand for Jaguar's products and effective market penetration, which can lead to improved financial stability and expansion opportunities.

Regulatory Advancements

Regulatory advancements for crofelemer could open new markets and applications, enhancing the company's product portfolio and long-term growth prospects.

Clinical Trial Success

Successful clinical trials for crofelemer enhance its credibility and potential for approval, supporting future revenue streams and market expansion.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially hindering the company's ability to invest in growth and weather economic downturns.

Operational Losses

Rising operational losses indicate inefficiencies and could strain resources, impacting the company's ability to sustain growth and profitability.

Negative Cash Flow

Negative cash flow trends highlight ongoing cash management issues, which can affect the company's ability to fund operations and strategic initiatives.

Jaguar Animal Health Business Overview & Revenue Model

Company Description

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

How the Company Makes Money

Jaguar Animal Health generates revenue primarily through the sale of its pharmaceutical products and veterinary therapeutics. The company has established a revenue model that includes direct sales to veterinarians and animal health distributors, as well as partnerships with larger pharmaceutical companies for product development and distribution. Key revenue streams include prescription medications and potential royalties from collaborations. Additionally, Jaguar may engage in licensing agreements for its proprietary technologies, further enhancing its financial performance. Significant partnerships with veterinary practices and discussions with animal food companies also contribute to its earnings, as they help broaden the reach and application of its products in the market.

Jaguar Animal Health Financial Statement Overview

Summary

Jaguar Animal Health faces substantial financial challenges with high leverage, consistent net losses, and negative cash flows. Despite some revenue growth and strong gross margins, the company struggles with operational inefficiencies and high debt levels.

Income Statement

Jaguar Animal Health has shown a mixed performance with inconsistent revenue growth. The revenue grew by approximately 18.38% from 2023 to 2024 but showed a decline previously. Gross profit margins are reasonably high, but the company struggles with negative EBIT and net income margins, indicating ongoing operational and profitability challenges.

Balance Sheet

The company's balance sheet indicates high leverage with a Debt-to-Equity ratio of approximately 5.63 in 2024, reflecting significant reliance on debt financing. The return on equity is negative due to consistent net losses, and the equity ratio is low, suggesting financial instability and potential risks related to excessive debt.

Cash Flow

Cash flow analysis reveals a negative trend in free and operating cash flows, although there was a slight improvement from 2023 to 2024. The company managed to secure significant financing cash flows, which have been covering operational deficits. However, the negative free cash flow to net income ratio highlights ongoing cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.79M	11.69M	9.76M	11.96M	4.33M	9.38M
Gross Profit	9.09M	9.73M	7.72M	9.94M	2.00M	6.11M
EBITDA	-41.16M	-36.66M	-32.76M	-33.38M	-42.37M	-28.74M
Net Income	-40.29M	-38.49M	-41.30M	-47.45M	-52.59M	-33.81M
Balance Sheet
Total Assets	49.47M	53.42M	50.76M	47.45M	53.27M	42.84M
Cash, Cash Equivalents and Short-Term Investments	3.53M	8.00M	6.47M	5.47M	17.05M	8.09M
Total Debt	31.90M	36.53M	37.09M	34.84M	29.36M	16.21M
Total Liabilities	45.11M	46.93M	45.87M	48.81M	41.41M	25.64M
Stockholders Equity	5.63M	7.29M	4.96M	-657.00K	11.61M	17.20M
Cash Flow
Free Cash Flow	-26.08M	-29.61M	-33.24M	-34.78M	-34.98M	-15.29M
Operating Cash Flow	-26.02M	-29.38M	-33.24M	-33.10M	-34.97M	-15.28M
Investing Cash Flow	-269.00K	-231.00K	0.00	-1.68M	-6.00K	-7.00K
Financing Cash Flow	16.71M	31.20M	34.23M	23.18M	43.94M	19.49M

Jaguar Animal Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.28
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JAGX, the sentiment is Negative. The current price of 1.28 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.37, and below the 200-day MA of 3.13, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.01 is Neutral, neither overbought nor oversold. The STOCH value of 72.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JAGX.

Jaguar Animal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GLMD	44 Neutral	$4.57M	-0.24	-46.34%	―	―	70.71%
DRMA	44 Neutral	$2.24M	-0.11	-203.36%	―	―	90.53%
SNGX	43 Neutral	$14.73M	-0.39	-169.32%	―	―	53.13%
REVB	43 Neutral	$5.39M	-0.03	-118.88%	―	―	96.26%
SXTP	43 Neutral	$2.09M	-0.07	-152.19%	―	192.72%	83.61%
JAGX	41 Neutral	$4.07M	-0.03	-370.95%	―	12.45%	-544.23%

Jaguar Animal Health Corporate Events

Jaguar Health Executes Strategic Stock Exchange Agreements

On June 27, 2025, Jaguar Health, Inc. engaged in a transaction with Iliad Research and Trading, L.P., issuing 170 shares of Series M Perpetual Preferred Stock. Later, on December 9 and December 11, 2025, Jaguar Health entered into two separate exchange agreements with Iliad, resulting in the issuance of a total of 440,000 shares of common stock and pre-funded warrants to purchase 1,609,372 shares in exchange for 91 shares of Series M Preferred Stock, which were subsequently cancelled. These transactions reflect strategic financial maneuvers by Jaguar Health to manage its stock and capital structure, potentially impacting its market positioning and shareholder dynamics.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Health Announces Promising Trial Results for Crofelemer

On December 8, 2025, Jaguar Health held a Special Meeting where stockholders approved three proposals, including the issuance of new shares and potential meeting adjournments. The company also announced promising initial results from a trial of crofelemer for infants with microvillus inclusion disease, highlighting its potential to reduce parenteral support needs. This development, alongside a recent FDA meeting, suggests a possible expedited approval pathway, impacting Jaguar’s market positioning and stakeholder interests.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Health Amends Royalty Interests and Note Terms

On November 17, 2025, Jaguar Health, Inc. announced amendments to its royalty interests with Iliad Research and Trading, Uptown Capital, and Streeterville Capital, setting a minimum monthly royalty payment starting April 1, 2026. Additionally, the company extended the maturity date of a secured promissory note with Streeterville to April 1, 2026. In a separate exchange transaction, Jaguar Health issued common stock to Streeterville in exchange for preferred stock, which was then cancelled.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.

Jaguar Animal Health Secures $10.8M Note Agreement

On November 12, 2025, Jaguar Health, Inc. entered into a note purchase agreement with Streeterville Capital, LLC, issuing a secured promissory note worth $10,810,000. The agreement includes an original issue discount and legal fees, with funds allocated to a newly formed subsidiary, JAGX Holdings, LLC. The note carries an 8% annual interest rate, with a 36-month maturity period, and includes provisions for mandatory prepayments and redemption rights. The company’s obligations are secured by various agreements, and certain covenants restrict Jaguar Health’s financial activities, ensuring compliance with the lender’s terms.

The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.